Navigation Links
UC-developed technology to assist research and genetic drug delivery

Techulon, Inc., and UC sign worldwide exclusive license agreements to manufacture and sell novel reagents used for research and therapeutic delivery of nucleic acids.

Techulon, Inc., a life sciences company, has signed worldwide exclusive license agreements with the University of Cincinnati to manufacture and sell novel transfection reagents used for research and therapeutic delivery of nucleic acids. The licenses cover a family of new molecules invented by Theresa M. Reineke while she was a faculty member in the Chemistry Department of the McMicken College of Arts & Sciences and described in two patent applications filed by UC.

"The polymeric transfection agents we have licensed from the University of Cincinnati are an exact fit for our business," states Frank Akers, president of Techulon. "Our ionic biopolymer expertise and infrastructure allow us to bring products to market almost immediately. Our first product, Glycofect, is especially effective in transfecting DNA into cells because of its low toxicity and efficiently induced transgene expression. These qualities make Glycofect especially suitable for sensitive and difficult-to-transfect cell lines or primary cells."

Marketed under the name of Glycofect Transfection Reagent, the new polymer-based formulations demonstrate unparalleled efficacy for delivering genetic materials into a variety of cell types for health-related research and drug development.

In contrast to currently used lipid-based transfection reagents that dominate a growing $100 million market, Techulon's products are based on novel carbohydrate polymer structures invented by Reineke, now an associate professor of chemistry at Virginia Tech.

"This new class of polymers can deliver DNA research reagents and therapeutics into a high number of cells and tissues types without causing cell damage or death," Reineke says. "After cellular delivery, the glycopolymers degrade and release their DNA cargo to perform its biological function without toxic side effects."

"We intend to expand our transfection reagent offerings, plus we have sublicenses available for companies needing a highly efficient vector with low toxicity to aid in their drug discovery," says Akers. "Techulon has strong developmental and synthetic capabilities headed up by Joshua Bryson, who studied under world-renowned biomaterials researcher Theresa Reineke at the University of Cincinnati. Techulon will work in partnerships to tailor our delivery vehicles for optimal effectiveness of novel genetic tools and drugs."

Bryson, principal scientist at Techulon, adds, "The exceptional delivery, high gene expression, and low toxicity of GlycofectTM are particularly evident in primary cells. This is of great benefit to biological and medical research because current transfection reagents do not work well with primary cells and these cell types are very costly and difficult to obtain."

GlycofectTM has been sampled to a number of medical research laboratories that have identified a broad spectrum of applications. In some cases, Techulon is cooperating with researchers to tailor the GlycofectTM formulations to optimize results for a variety of applications including siRNA delivery. GlycofectTM will be available for purchase as a transfection reagent for research applications on April 1, 2010. Techulon also plans to sublicense GlycofectTM for therapeutic development.


Contact: Wendy Beckman
University of Cincinnati

Related biology news :

1. Yale scientists use nanotechnology to fight E. coli
2. Voice Biometrics Gains Traction as Most Accurate and Convenient Technology to Secure Customer Privacy
3. M2SYS Partners with SecuGen Corporation to Support Market Leading Hamster Plus Fingerprint Reader with Auto-On Technology
4. Silicon Valley Technology Leaders LaserCard Corporation and Tesla Motors Sign LaserPass Secure Access Deal
5. Nanotechnology: Whats that?
6. UCs NIH grant brings technology from outer space to playgrounds
7. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
8. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
9. UCLA/VA partners with ASU to advance biosensor technology for urinary tract infections
10. Herr receives Heinz Award for Technology, the Economy and Employment
11. Singapore National Science and Technology Awards
Post Your Comments:
Related Image:
UC-developed technology to assist research and genetic drug delivery
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... Technology and Patent Infringement Risk Analysis" report to ... --> Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:11/19/2015)... Nov. 19, 2015  Based on its in-depth analysis ... recognizes BIO-key with the 2015 Global Frost & Sullivan ... & Sullivan presents this award to the company that ... the needs of the market it serves. The award ... and expands on customer base demands, the overall impact ...
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific discoveries ... doctors and other healthcare providers face challenges in better ... and patients. In addition, as more children continue to ... patient,s adulthood and old age. John M. ... Children,s Hospital of Philadelphia (CHOP) . --> ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Researchers at the ... Institute for Brain Research at MIT have engineered changes ... cut down on "off-target" editing errors. The refined technique ... use of genome editing. Science , ... three of the approximately 1,400 amino acids that make ...
(Date:12/1/2015)... VIEW, Calif. , Dec. 1, 2015 /PRNewswire/ ... the Transformational Health program. This program addresses ways ... period of change. ... Logo - ... every aspect of healthcare, as well as the ...
(Date:12/1/2015)... ROSEVILLE, Minn. , Dec. 1, 2015  The ... the recipient of the 2015 Tekne Award in the ... th at the Minneapolis ... who have played a significant role in developing new ... people living around the world. Clostridium difficile ...
(Date:12/1/2015)... , Dec. 1, 2015  CardioCell LLC, a ... stem cells for cardiovascular indications, intends to proceed ... based on recommendations from a Heart Failure Advisory ... Scientific Advisory Board members . In a ... Phase IIa safety and efficacy data from CardioCell,s ...
Breaking Biology Technology: